Humacyte is trading at $0.40, down 10.11%, with the reason for the November 5 decline unclear. - No clearly verified company-specific announcement explains the decline; Humacyte’s third-quarter results are scheduled for November 10. - The Nasdaq is down 4.23% and the S&P 500 is down 2.74%, while biotech is up 2.05%, so the move does not appear to track the sector.